Evidence map›Paper›PMID 40570203›Full record

ArticleJournal of the American Chemical Society2025

Near-Infrared Light-Accelerated Bioorthogonal Drug Uncaging and Photothermal Ablation by Anisotropic Pd@Au Plasmonic Nanorods.

M Carmen Ortega-Liebana, Jana Travnickova, Catherine Adam, Davir González-Calderón, Álvaro Lorente-Macías, Charles Lochenie, Raul Arenal, E Elizabeth Patton, Asier Unciti-Broceta

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Highly Active CuAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M Carmen Ortega-LiebanaDepartment of Medicinal and Organic Chemistry and Unit of Excellence in Chemistry Applied to Biomedicine and Environment, Campus Cartuja s/n, University of Granada, Granada 18071, Spain.ORCID 0000-0001-5835-1223
Jana TravnickovaEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.ORCID 0000-0002-8339-9162
Catherine AdamEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
Davir González-CalderónEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
Álvaro Lorente-MacíasEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.ORCID 0000-0001-9510-714X
Charles LocheniePandemic Science Hub, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, U.K.
Raul ArenalLaboratorio de Microscopias Avanzadas (LMA), Universidad de Zaragoza, Zaragoza 50018, Spain.ORCID 0000-0002-2071-9093
E Elizabeth PattonEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
Asier Unciti-BrocetaEdinburgh Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.ORCID 0000-0003-1029-2855

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective activation of chemotherapeutics at the tumor site via bioorthogonal catalysis is a promising strategy to reduce collateral damage to healthy tissues and organs. Despite significant advances in this field, targeted drug activation by transition-metal catalysts is still limited by insufficient spatiotemporal control over the metal-mediated uncaging process. Herein, we report the development of anisotropic Pd@Au plasmonic nanorods with the capacity to accelerate dealkylation reactions under near-infrared (NIR) irradiation, thereby enabling precise control over when and where these catalytic devices are switched on. We also show that the stability and

Indexed as

Antineoplastic AgentsGoldInfrared RaysNanotubesPalladiumPhotothermal TherapyProdrugsAnimalsAnisotropyCell Line, TumorDrug LiberationHumansZebrafishAntineoplastic AgentsGoldPalladiumProdrugs

Identifiers

PMID40570203
PMCPMC12257503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.